EcoDrugPlus

Polo Like Kinase 4

Ensembl ID : ENSBGRG00000008016
Gene Symbol: PLK4
1 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSBGRG00000005223
Gene Symbol: PARP1
1 Cross references
206 Possible Orthologues:

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSBGRG00000025863
Gene Symbol: PARP3
1 Cross references
200 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSBGRG00000018078
Gene Symbol: PORCN
1 Cross references
266 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSBGRG00000021722
Gene Symbol: KCNMA1
1 Cross references
297 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily N Member 4

Ensembl ID : ENSBGRG00000010498
Gene Symbol: KCNN4
1 Cross references
191 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSBGRG00000009694
Gene Symbol: KCNJ11
1 Cross references
190 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSBGRG00000026471
Gene Symbol: KCNJ2
1 Cross references
273 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSBGRG00000007869
Gene Symbol: KCNJ3
1 Cross references
229 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSBGRG00000024265
Gene Symbol: KCNJ5
1 Cross references
213 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSBGRG00000019112
Gene Symbol: KCNK2
1 Cross references
284 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 3

Ensembl ID : ENSBGRG00000010821
Gene Symbol: KCNK3
1 Cross references
202 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).